Michael M. Tarnow - May 18, 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Stock symbol
XENE
Transactions as of
May 18, 2021
Transactions value $
$30,612
Form type
4
Date filed
5/20/2021, 04:18 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $7.96K +2.06K +2.95% $3.87 71.8K May 18, 2021 Direct F1, F2
transaction XENE Common Shares Options Exercise $3.77K +1.03K +1.43% $3.67 72.8K May 18, 2021 Direct F1, F2
transaction XENE Common Shares Options Exercise $18.9K +5.14K +7.07% $3.67 77.9K May 18, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -2.06K -100% $0.00* 0 May 18, 2021 Common Shares 2.06K $3.87 Direct F2, F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -1.03K -100% $0.00* 0 May 18, 2021 Common Shares 1.03K $3.67 Direct F2, F4
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -5.14K -100% $0.00* 0 May 18, 2021 Common Shares 5.14K $3.67 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021.
F2 The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F3 The shares subject to the option fully vested on July 1, 2014.
F4 1/3 of the shares subject to the Option vested on January 1, 2013 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 2 years.